Guidance on the management of Diabetic Ketoacidosis in the exceptional circumstances of the COVID-19 pandemic

G. Rayman (Lead / Corresponding author), A. Lumb, B. Kennon, C. Cottrell, D. Nagi, E. Page, D. Voigt, H. Courtney, H. Atkins, J. Platts, K. Higgins, K. Dhatariya, M. Patel, P. Narendran, P. Kar, P. Newland-Jones, R. Stewart, O. Burr, S. Thomas

Research output: Contribution to journalLetter

2 Citations (Scopus)

Abstract

During the early stages of the COVID‐19 pandemic, hospitals in London, the UK epicentre, reported an unusually high number of people presenting with COVID‐19 disease developing diabetic ketoacidosis, hyperosmolar hyperglycaemic state, or a combination of both. Very high doses of insulin were often needed to manage the hyperglycaemia. It has been proposed that these metabolic disturbances may result from severe insulin resistance combined with decreased insulin secretion due to beta cell dysfunction.
Original languageEnglish
Pages (from-to)1214-1216
Number of pages3
JournalDiabetic Medicine
Volume37
Issue number7
Early online date18 May 2020
DOIs
Publication statusPublished - 18 Jun 2020

Fingerprint Dive into the research topics of 'Guidance on the management of Diabetic Ketoacidosis in the exceptional circumstances of the COVID-19 pandemic'. Together they form a unique fingerprint.

  • Cite this

    Rayman, G., Lumb, A., Kennon, B., Cottrell, C., Nagi, D., Page, E., Voigt, D., Courtney, H., Atkins, H., Platts, J., Higgins, K., Dhatariya, K., Patel, M., Narendran, P., Kar, P., Newland-Jones, P., Stewart, R., Burr, O., & Thomas, S. (2020). Guidance on the management of Diabetic Ketoacidosis in the exceptional circumstances of the COVID-19 pandemic. Diabetic Medicine, 37(7), 1214-1216. https://doi.org/10.1111/dme.14328